JPS63112515A - Spray dried acetaminophen - Google Patents
Spray dried acetaminophenInfo
- Publication number
- JPS63112515A JPS63112515A JP62266140A JP26614087A JPS63112515A JP S63112515 A JPS63112515 A JP S63112515A JP 62266140 A JP62266140 A JP 62266140A JP 26614087 A JP26614087 A JP 26614087A JP S63112515 A JPS63112515 A JP S63112515A
- Authority
- JP
- Japan
- Prior art keywords
- acetaminophen
- powder
- weight
- spray
- colloidal silica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 37
- 239000007921 spray Substances 0.000 title description 21
- 239000000843 powder Substances 0.000 claims abstract description 33
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 24
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 24
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000008119 colloidal silica Substances 0.000 claims abstract description 17
- 239000002552 dosage form Substances 0.000 claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000007910 chewable tablet Substances 0.000 claims abstract description 7
- 239000000725 suspension Substances 0.000 claims abstract description 6
- 238000001694 spray drying Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012876 carrier material Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229940088679 drug related substance Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 239000012907 medicinal substance Substances 0.000 claims 2
- 229940068682 chewable tablet Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000002156 mixing Methods 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 230000009967 tasteless effect Effects 0.000 description 12
- 108010010803 Gelatin Proteins 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 235000012431 wafers Nutrition 0.000 description 4
- 206010013911 Dysgeusia Diseases 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 241000585703 Adelphia <angiosperm> Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- AMTPYFGPPVFBBI-UHFFFAOYSA-N acedapsone Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)C1=CC=C(NC(C)=O)C=C1 AMTPYFGPPVFBBI-UHFFFAOYSA-N 0.000 description 1
- 229950009438 acedapsone Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000021572 root beer Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Description
【発明の詳細な説明】
Σζ則至分顆
本発明は、例え:、1′米国特許第4,305,502
号および第4.371,516号並びに英国特許明細書
第1,548,022号に記載のような咀しやく錠およ
び速やかに溶解する投与形に処方できろ新規治療形の無
味のスプレードライしたアセトアミノフェンに関する。DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the Σζ law, for example: 1' U.S. Pat. No. 4,305,502
No. 4,371,516 and British Patent Specification No. 1,548,022, a new therapeutic form of tasteless spray-dried Regarding acetaminophen.
さらに詳しくは、本発明は、コロイド状シリカを懸濁さ
せた、低アルカノール中のアセトアミノフェンおよびエ
チルセルロースの溶液をスプレードライすることにより
生成されるスプレードライした粉末に関する。該スプレ
ードライした粉末は無味である。「無味」とは、該粉末
が基本的に味がなくかつ甘くも苦くもないことを意味す
る。More particularly, the present invention relates to a spray-dried powder produced by spray-drying a solution of acetaminophen and ethylcellulose in a low alkanol in which colloidal silica is suspended. The spray dried powder is tasteless. "Tasteless" means that the powder is essentially tasteless and neither sweet nor bitter.
発明の背景
アセトアミノフェン(またはバラセタモールとして知ら
れる)は広く鎮痛剤および解熱剤として用いられろが、
固体タイプの投与形をそのまま飲みこめない人々にとっ
て咀しやくタイプの錠剤で用いるのには充分に味の良い
ものではない。BACKGROUND OF THE INVENTION Acetaminophen (also known as valacetamol) is widely used as an analgesic and antipyretic;
It is not palatable enough to be used in chewable tablets for people who cannot swallow solid dosage forms whole.
フレーバー、例えば、チョコレート、バナナ、オレンジ
、レモン、リコリス、ルートビヤ−およびラズベリーは
特に苦味のある薬剤用に提案されてきた。これらのフレ
ーバーは信頼できるマスキング成分ではない。ミントフ
レーバーは粉つぼい呈味特性を改良するのに有用である
。しかしながら、苦味特性は、特にフレーバーが期待さ
れる本来の味に似ない場合、それを大きくマスキングす
るのは非常に難かしい。Flavors such as chocolate, banana, orange, lemon, licorice, root beer and raspberry have been proposed especially for bitter-tasting drugs. These flavors are not reliable masking ingredients. Mint flavor is useful in improving the chalky taste characteristics. However, bitterness properties are very difficult to mask to a large extent, especially when the flavor does not resemble the expected native taste.
咀しゃく錠、或いは咀しやくタイプの錠剤の経口による
受は入れを考慮すると、口当たりを含む他の特性も取扱
う必要がある。When considering oral acceptance of chewable tablets or chewable tablets, other characteristics, including mouthfeel, need to be addressed.
米国特許第4,305,502号および第4.371.
516号並びに英国特許第1.54.8,022号に記
載の速やかに溶解する投与形は10秒以内、例えば5秒
以下で水に崩解ずろように製造されるので、口腔内の唾
液で速やかに溶解する。このような経口投与用投与形は
、単位投与量の医薬物質を担持する医薬上許容される水
溶性或いは水分散性の担体材料(例えばゼラチン)のネ
ットワークからなることが可能であり、該投与形が10
秒以内に水で崩解できるように、該担体材料が該医薬物
質に対して不活性であり、該ネットワークが、医薬物質
および溶媒中の担体材料の溶液からなる固体状態の組成
物から溶媒を昇華することによって得られる。従来、こ
のような投与形の使用は、フレーバーによってマスキン
グできる無味であるか、或いは不快な味が僅かな医薬に
限定されていた。しかしながら、アセトアミノフェンの
ような苦味を有する医薬は、従来、このような投与形で
用いることができなかった。U.S. Patent Nos. 4,305,502 and 4.371.
The rapidly dissolving dosage forms described in No. 516 and British Patent No. 1.54.8,022 are manufactured in such a way that they disintegrate in water within 10 seconds, for example within 5 seconds, so that saliva in the oral cavity Dissolves quickly. Such oral dosage forms may consist of a network of pharmaceutically acceptable water-soluble or water-dispersible carrier materials (e.g. gelatin) carrying a unit dose of the drug substance; is 10
The carrier material is inert to the drug substance such that it can be disintegrated in water within seconds and the network removes the solvent from a solid state composition consisting of the drug substance and a solution of the carrier material in a solvent. Obtained by sublimation. Traditionally, the use of such dosage forms has been limited to medicinal products that are tasteless or have a slight unpleasant taste that can be masked by flavoring. However, pharmaceuticals with a bitter taste, such as acetaminophen, have not heretofore been able to be used in such dosage forms.
発明の開示
本発明によれば、咀しやく錠等に処方できる、新規治療
用の無味粉末形のスプレードライしたアセトアミノフェ
ンが提供される。該粉末は、コロイド状シリカを懸濁さ
せた、低アルカノール中のアセトアミノフェンおよびエ
チルセルロースの溶液をスプレードライするごとにより
生成されろ。DISCLOSURE OF THE INVENTION In accordance with the present invention, there is provided a novel therapeutic spray-dried acetaminophen in the form of a tasteless powder that can be formulated into chewable tablets and the like. The powder is produced by spray drying a solution of acetaminophen and ethyl cellulose in a low alkanol in which colloidal silica is suspended.
好ましくは、該低アルカノールはエタノールである。Preferably, the lower alkanol is ethanol.
本発明は、特に、該粉末重量に基づく、約・10〜70
重量%のアセトアミノフェン、約15〜30重量%のエ
チルセルロースおよび約15〜30重量%のコロイド状
シリカからなり、該粉末が、アセトアミノフェンおよび
エチルセルロースの低アルカノール溶液中のコロイド状
シリカのIIJ、 E液からスプレードライしてなる治
療粉末形のスプレードライしたアセトアミノフェンを提
供するものである。The present invention particularly provides about .10 to 70
IIJ of colloidal silica in a low alkanol solution of acetaminophen and ethyl cellulose, wherein the powder is comprised of % by weight acetaminophen, about 15-30% by weight ethylcellulose and about 15-30% by weight colloidal silica; The present invention provides spray-dried acetaminophen in the form of a therapeutic powder that is spray-dried from Solution E.
本発明の他の態様によれば、該投与形が37℃の水で1
0秒以内に崩解でき、本発明の無味粉末形のスプレード
ライしたアセトアミノフェンに処方されろ薬剤からなる
固体経口投与用の医薬投与形が提供される。According to another aspect of the invention, the dosage form is
A solid pharmaceutical dosage form for oral administration is provided which can be disintegrated within 0 seconds and comprises the drug formulated into spray-dried acetaminophen in the form of a tasteless powder of the present invention.
本発明において有用なアセトアミノフェンは医薬グレー
ドであっても良い。本発明において有用なエチルセルロ
ースは、また、国際処方或いは医薬グレードであっても
良い。適当なグレードとしては、ダウ・ケミカル・カン
パニー・ミツトランド壷ミシガン(Dow C1+e
mical Company。Acetaminophen useful in the present invention may be of pharmaceutical grade. Ethylcellulose useful in the present invention may also be international formulation or pharmaceutical grade. Suitable grades include Dow Chemical Company Mittland Pot Michigan (Dow C1+e
mical Company.
M 1dland Michigan)およびバーキ
ュレス・インク・才ブ・ウィルミントン・プラウエア(
1−1ercuIes、 Inc、 ofWilmi
ngton、 Delaware)により市場に出さ
れているエトセル(E’l”f(QCEL)ブランドを
包含する。M1dland Michigan) and Bercules, Inc., Wilmington Plowea (
1-1ercuIes, Inc, of Wilmi
ngton, Delaware).
本発明において有用なコロイド状シリカは約10ミクロ
ンの粒径を有する。適当なグレードはカボット・コーポ
レーション・オブ・ボストン、マザチューセッツ(Ca
bot Corporation ofI3ost
on、 Massachusetts)により市場に出
されているカーボンル(Carbosil)−M −5
であり、ビーキュー・カンパニー、フィラデルフィア、
ベンンルベニア(PQ Company、 Ph1l
adelphia。Colloidal silica useful in the present invention has a particle size of about 10 microns. Suitable grades are Cabot Corporation of Boston, Mazachusetts
bot Corporation ofI3ost
Carbosil-M-5, marketed by Carbosil, Massachusetts,
and BQ Company, Philadelphia;
Bennruvenia (PQ Company, Ph1l
adelphia.
P ennsylvania)により販売されている。P ennsylvania).
粉末中のアセトアミノフェンの重量%は約40〜70重
量%とすることができ、エチルセルロースの重量%は約
15〜30重量%の範囲とすることができる。エチルセ
ルロースが15重爪形では僅かな苦味があるが、20%
以上では該粉末は無味である。粉末中のコロイド状シリ
カの重量%は約15〜30重量%とすることがてきる。The weight percent of acetaminophen in the powder can range from about 40 to 70 weight percent, and the weight percent of ethylcellulose can range from about 15 to 30 weight percent. Ethyl cellulose has a slight bitterness in the 15-fold nail shape, but 20%
Above this, the powder is tasteless. The weight percent of colloidal silica in the powder can be about 15-30 weight percent.
エチルセルロース用の溶媒はメチル、エチル、イソプロ
ピルまたはその混合物のような1つのアルカノールが可
能であるが、アセトアミノフェンか可溶である有機溶媒
でなければならない。「低アルカノール」とは、1〜4
個の炭素原子を含有ずろアルカノールを意味する。The solvent for ethylcellulose can be an alkanol such as methyl, ethyl, isopropyl or mixtures thereof, but must be an organic solvent in which acetaminophen is soluble. "Low alkanol" means 1 to 4
means an alkanol containing 5 carbon atoms.
スプレードライした粉末からアセトアミノフェンが浸出
するのを抑制するため、ひまし浦のような少h1の疎水
性物質を溶液に添加できる。味マスキングを改良するた
め、少量のモノステアリン酸グリセリンを添加てきる。To inhibit leaching of acetaminophen from the spray-dried powder, a low h1 hydrophobic material such as Himashiura can be added to the solution. A small amount of glyceryl monostearate may be added to improve taste masking.
スプレードライヤーは通常の実験室或いは商業的タイプ
が可能である。適当なスプレードライヤーはプツチ・ラ
ボラトリウムズーテクニック・エイノー(Buchi
Laboratoriums−TechnicAG)
、ザ・アンヒドロ・カンパニー・オブ・アットレホロ、
マザヂューセッツ(the A nhydr。The spray dryer can be of the conventional laboratory or commercial type. A suitable spray dryer is Buchi Laboratorium Zoo Technique Eino.
Laboratoriums-Technic AG)
, The Anhydro Company of Atrehoro,
Mazaju Sets (the A nhydr.
Company of Attleboro、
MassachuseHs)およびエコ・アトマイ
ザ−・インク・オブ・コロンビア、メリーランド(Ni
ro Δしomizer I nc、 。Company of Attleboro,
MassachuseHs) and Eco Atomizer Inc. of Columbia, Maryland (Ni
roΔomizer Inc.
of’ Columbia、 Maryland)に
より製造されろ。of Columbia, Maryland).
以下の実施例で用いられるスプレードライヤーはプツチ
190タイプのミニスプレードライヤーてあった。プツ
チ社製ミニスプレードライヤーの操作条件は、習慣的に
吸気口温度が220°Cおよび排気口温度が130℃で
ある。The spray dryer used in the following examples was a Petit 190 type mini spray dryer. The operating conditions for the Petit mini spray dryer are customarily an inlet temperature of 220°C and an outlet temperature of 130°C.
以下の実施例は本発明の無味のスプレードライしたアセ
トアミノフェン粉末の生成を示す。これらの実施例にお
いて、エチルセルロースはハーキュルズ・ケミカル・カ
ンパニー、ウィルミントン、プラウエア(Ilercu
les Chemical Company。The following examples demonstrate the production of tasteless, spray-dried acetaminophen powders of the present invention. In these examples, ethylcellulose is manufactured by Hercules Chemical Company, Wilmington, Ilercu.
les Chemical Company.
Wilmington、 Delaware)から得た
。該エチルセルロースは、粘度指数カ月0でかつ48.
0〜495%のエトキン含ITffiを有する標準タイ
プの乾燥物質であった。Wilmington, Delaware). The ethyl cellulose has a viscosity index of 0 and 48.
It was a standard type dry material with an ITffi of 0-495%.
以下の実施例により本発明をさらに具体的に説明ずろ。The present invention will be explained in more detail with reference to the following examples.
実、鋤例1
本実施例において、スプレードライヤーへの供給混合物
は以下の物質からなっていた。In fact, Example 1 In this example, the feed mixture to the spray dryer consisted of the following materials:
11SP 70 7
0 85エヂルセルロース、NF +5
15 1gコロイド状シリカ +5
15 15エチルアルコール −250
0m(!まで追は
合計: 1009.< 100%
2600ライトニンミキザーを用いてステンレス:A
製〆見合容器内のアルコールの1部にアセトアミノフェ
ンを溶解させた。別のステンレス犯1製混合容器内の残
りのアルコールにエチルセルロースを溶解させ、次いで
該2側の混合容2);の内容物を濾過・混合した。均一
な分散液が得られるまでコロイド状シリカを添加・混合
した。次いて該分散液をブヂ社製ミニスプレードライヤ
ーの供給ポツパーに移した。11SP 70 7
0 85 edyl cellulose, NF +5
15 1g colloidal silica +5
15 15 ethyl alcohol -250
0m (total up to !: 1009.<100%
Stainless steel using 2600 Lightnin mixer: A
Acetaminophen was dissolved in one part of the alcohol in the container. Ethyl cellulose was dissolved in the remaining alcohol in another stainless steel mixing container 1, and then the contents of the mixing container 2) on the two sides were filtered and mixed. Colloidal silica was added and mixed until a uniform dispersion was obtained. The dispersion was then transferred to the supply popper of a Buji mini spray dryer.
運転中、吸気口温度220〜225°Cおよび排気口温
度150〜155°Cを保持するようにスプレードライ
ヤーを操作しf二。During operation, the spray dryer was operated to maintain an inlet temperature of 220-225°C and an outlet temperature of 150-155°C.
スプレードライした粉末の収率は理論的収率の約90%
であった。生成物は、その95%が2〜50ミクロンの
粒径を有する白色の細かい粉末であった。The yield of spray-dried powder is approximately 90% of the theoretical yield.
Met. The product was a fine white powder, 95% of which had a particle size of 2-50 microns.
新たに得た生成物は、味わうとアセトアミノフェンの苦
味特性を生じなかった。室温で1ケ月間のエージングを
行ったが、生成物は相変わらず苦味のない事実上許容さ
れるものであった。The freshly obtained product did not produce the bitter characteristics of acetaminophen when tasted. After one month of aging at room temperature, the product remained virtually acceptable with no bitter taste.
実施例2 本実施例において、成分量を以下のように変更した。Example 2 In this example, the component amounts were changed as follows.
エチルセルロース、NP15 15 15
コロイド状ンリカ 15 15 15
合計:100% 100% た1600運転中、吸気
口温度220〜225°Cおよび排気口温度150〜1
55℃を保持するようにスプレードライヤーを操作した
。Ethyl cellulose, NP15 15 15
Colloidal Nrica 15 15 15
Total: 100% 100% During 1600 operation, inlet temperature 220-225°C and outlet temperature 150-1
The spray dryer was operated to maintain a temperature of 55°C.
実施例3 本実施例において、成分量を以下のように変更した。Example 3 In this example, the component amounts were changed as follows.
USP 40 40
40エチルセルロース、NP30 30
30コロイド状シリカ 30 30
30合計:100% 100% た2600運転中、
吸気口温度220〜225℃および排気口温度150〜
155℃を保持するようにスプレードライヤーを操作し
た。USP 40 40
40 ethyl cellulose, NP30 30
30 Colloidal Silica 30 30
30 total: 100% 100% 2600 driving,
Inlet temperature 220~225℃ and exhaust outlet temperature 150~
The spray dryer was operated to maintain a temperature of 155°C.
該スプレードライヤーから得た生成物は、味わうと苦味
を生じなかった。The product obtained from the spray dryer did not taste bitter when tasted.
実施例4
本実施例において、イソプロピルアルコールをエチルア
ルコールの代わりに用い、スプレードライヤーへの供給
混合物は以下の物質からなっていた。Example 4 In this example, isopropyl alcohol was used in place of ethyl alcohol and the feed mixture to the spray dryer consisted of the following materials:
アセトアミノフェン、t!SP 70 23
.33イソプロピルアルコール −200,00エチ
ルセルロース、NF L5 5.00コロ
イド状シリカ 15 5.00イソプロ
ピルアルコール −500mCまで適量
合計:100%
ライトニンミキサーを用いてステンレス鋼製混合容器内
のアルコールの1部にアセトアミノフェンを溶解させた
。80%のアセトアミノフェンが30分間で溶解し、9
0%が60分後に溶解し、次いで少量の残基を除き、3
時間ですべてが溶解した。別のステンレス鋼製混合容器
内のアルコールの1部にエチルセルロースを溶解させた
。該エチルセルロースは2時間でも溶解しなかったが、
−夜装置すると朝にはほとんど溶解した。ライトニンミ
キサーで1時間混合すると完全に溶解した。Acetaminophen, t! SP 70 23
.. 33 Isopropyl Alcohol -200,00 Ethyl Cellulose, NF L5 5.00 Colloidal Silica 15 5.00 Isopropyl Alcohol -Adequate to 500mC Total: 100% Add acetamin to one part of the alcohol in a stainless steel mixing vessel using a lightnin mixer. Phen was dissolved. 80% of acetaminophen dissolves in 30 minutes, 9
0% dissolved after 60 minutes, then removed a small amount of residue and
Everything dissolved in time. Ethylcellulose was dissolved in a portion of alcohol in a separate stainless steel mixing vessel. Although the ethylcellulose did not dissolve even for 2 hours,
- When the device was used at night, most of it had dissolved in the morning. After mixing for 1 hour with a lightnin mixer, it was completely dissolved.
次いで該2個の混合容器の内容物を合わせた。均一な分
散液が得られるまでコロイド状ソリ力を添加・混合した
。次いでイソプロピルアルコールを500mσまで適量
添加した。該分散液をプツチ社製ミニスプレードライヤ
ーの供給タンクに移した。The contents of the two mixing vessels were then combined. Colloidal warping force was added and mixed until a uniform dispersion was obtained. Then, an appropriate amount of isopropyl alcohol was added to the solution up to 500 mσ. The dispersion was transferred to the supply tank of a mini spray dryer manufactured by Petit.
運転中、吸気口温度180〜185℃および排気口温度
113℃に保持するようにスプレードライヤーを操作し
た。During operation, the spray dryer was operated to maintain an inlet temperature of 180-185°C and an outlet temperature of 113°C.
新たに得た白色粉末は、味わうとアセトアミノフェンの
苦味特性を幾分か生じた。The freshly obtained white powder produced some of the bitter characteristics of acetaminophen when tasted.
実施例5
本実施例において、メタノールをエチルアルコールの代
わりに用い、スプレードライヤーへの供給混合物は以下
の物質からなっていた。Example 5 In this example, methanol was used in place of ethyl alcohol and the feed mixture to the spray dryer consisted of the following materials:
成 分 1500.v12@濁液当たりの
成分アセトアミノフェン、USP 210エ
チルセルロース、NP 45コロイド状シ
リカ 3メヂルアルコール
15QI)ff&まで適量ライトニンミキサーを備え
たステンレス掴製混合容器中に780Uの量のメタノー
ルを入れ、210りのアセトアミノフェンを添加した。Ingredients 1500. v12@Ingredients per suspension Acetaminophen, USP 210 Ethylcellulose, NP 45 Colloidal Silica 3 Methyl Alcohol
780 U of methanol was placed in a stainless steel mixing vessel equipped with a lightnin mixer, and 210 U of acetaminophen was added.
1時間混合した後、90%のアセトアミノフェンが溶解
した。ライトニンミキザーを備えた別のステンレス鋼製
混合容器中に690頭の量のメタノールを入れ、〆晶巻
きが生じるように速度を調整した。次いでエチルセルロ
ース(45y)を添加し、該エチルセルロースか溶解す
るまで1時間混合し続けた。After 1 hour of mixing, 90% of the acetaminophen was dissolved. A quantity of 690 methanol was placed in a separate stainless steel mixing vessel equipped with a light nin mixer and the speed was adjusted to produce crystallization. Ethylcellulose (45y) was then added and mixing continued for 1 hour until the ethylcellulose was dissolved.
該2個の混合容器の内容物を合わせ、メタノールを1b
00tcまで適量添加した。すべての固体が溶解するま
て1+時間混合し続けた。次いて、この500.!!2
の溶液を別の混合容Ma1.:序し、I9のコロイ)・
状シリカを、均一となるまで混合しながら添加した。コ
ロイド状シリカの分散液を改良しかつ溶液中の池の固体
を保持するため、19のモノステアリン酸グリセリン(
テンン(T egin) 515)を添加した。次いで
、該分散液をプツチ社製ポータプルスプレードライヤー
の供給タンクに移した。Combine the contents of the two mixing vessels and add 1b of methanol.
An appropriate amount was added up to 00tc. Mixing continued for 1+ hour until all solids were dissolved. Next, this 500. ! ! 2
The solution of Ma1. : Introduction, I9 Koroi)・
silica was added with mixing until uniform. Glyceryl monostearate (19) was used to improve the dispersion of colloidal silica and to retain pond solids in solution.
Tegin 515) was added. The dispersion was then transferred to the supply tank of a portable spray dryer manufactured by Petit.
遅転中、吸気温度120〜220°Cおよび排気口温度
78〜82°Cを保持するようにスプレードライヤーを
操作した。During the slow rotation, the spray dryer was operated to maintain an inlet temperature of 120-220°C and an outlet temperature of 78-82°C.
新たに得た生成物は、味わうと極く僅かな苦味があった
。The freshly obtained product had a very slight bitter taste when tasted.
スプレードライヤーから再度得た生成物の粒径は主に2
〜50ミクロンの範囲であり、該生成物の50%が20
ミクロンより小さい粒径を存し、100ミクロンより大
きい粒子はなかった。The particle size of the product obtained again from the spray dryer is mainly 2
~50 microns, with 50% of the product being 20
There were particle sizes smaller than microns and no particles larger than 100 microns.
新たにスプレードライヤーから得た生成物は、味わうと
口の中で極く僅かな苦味を生じた。粒子の知覚感知は約
20ミクロンであるので、粉末は良好な口当たりを生じ
た。The product freshly obtained from the spray dryer produced a very slight bitter taste in the mouth when tasted. The powder had a good mouthfeel as the particle size was approximately 20 microns.
実在例6
本実施例は、実施例1のスプレードライした無味のアセ
トアミ、ノフェンおよび以下の他成分を用L1fこ速や
かに溶解する投与形のII製について記載している。EXAMPLE 6 This example describes the preparation of a dosage form II that rapidly dissolves the spray-dried, tasteless acetamide of Example 1, nophene, and the following other ingredients.
ゼラチン、BY19150 4,0
10.00マンニツト、粒状 3.0
7.50脱イオン水 67.10
167.75ヂエリー# 271 0.
40 1.00ラウリル硫酸ナトリウム 0
.10 0.25実施例1の粉末 2
3.0 57.50前記懸さ8液の回分調製法は
2段階、すなわちゼラチンベースの調製および薬剤の添
加で生じる。Gelatin, BY19150 4,0
10.00 Mannite, granular 3.0
7.50 Deionized water 67.10
167.75 Jewelry # 271 0.
40 1.00 Sodium lauryl sulfate 0
.. 10 0.25 Powder of Example 1 2
3.0 57.50 The above-mentioned 8-liquid batch preparation process occurs in two steps: preparation of the gelatin base and addition of the drug.
ゼラチンベースは、30°Cの脱イオン水にゼラチンを
添加し、該ゼラチンが溶解するまで混合することにより
ff1JffJする。次いで、溶液を25℃まで冷却し
、マンニット、ラウリル硫酸ナトリウム、甘味料および
フレーバーを別々に添加し、溶解する。The gelatin base is prepared by adding gelatin to deionized water at 30°C and mixing until the gelatin is dissolved. The solution is then cooled to 25°C and the mannitol, sodium lauryl sulfate, sweetener and flavor added separately and dissolved.
粉末形のクロスカルメローズ(アクディゾル(AcDi
Soりおよび無味のスプレードライしたアセトアミノフ
ェン粉末を乾燥・混合し、20メツシユのスクリーンを
通してふるいを行った。該、′11合粉末をゼラチン溶
液に添加し、さらにホモミキサーで30分間混合して均
一な分散液を生成しfこ。Powdered croscarmellose (AcDisol)
Solute and tasteless spray-dried acetaminophen powder was dried and mixed and sieved through a 20 mesh screen. The '11 powder was added to the gelatin solution and mixed for 30 minutes using a homomixer to form a uniform dispersion.
本実施例においてフリーズドライヤーはフィルデス社製
25SRCモデルのフリーズドライヤーである。アセト
アミノフェンの懸濁液500nLiをトレイ毎に10個
のウェルを有する加熱成形したブリスタートレイ中に投
与することにより速やかに溶解する投与形を調製した。In this example, the freeze dryer is a 25SRC model freeze dryer manufactured by Fildes. A fast dissolving dosage form was prepared by administering 500 nLi of a suspension of acetaminophen into thermoformed blister trays with 10 wells per tray.
1ij4 fこしfこトレイを、乾燥した水−メタノー
ルの混合物を含有する大きいトレイ中に配置する。ウェ
ル中の懸濁液か律拮すると、貯蔵温度−45℃のフリー
ズドライヤートレイの上に配置する。Place the strainer tray into a larger tray containing the dry water-methanol mixture. Once the suspension in the wells is stable, place it on a freeze dryer tray at a storage temperature of -45°C.
ウェル中のプルーブによって測定されるように、サンプ
ルの温度が一45℃に達すると、コンデンサーをオンに
し、フリーザーをオフにする。該コンデンサー温度は−
40〜−45℃、真空を50〜60mmTorrとした
。次いでヒーターをオンにし、貯蔵温度を50〜55℃
に調整する。加熱−乾燥のサイクルを4時間継続する。When the temperature of the sample reaches 145°C, as measured by the probe in the well, turn on the condenser and turn off the freezer. The condenser temperature is -
The temperature was 40 to -45°C and the vacuum was 50 to 60 mm Torr. Then turn on the heater and keep the storage temperature at 50-55℃
Adjust to. The heat-dry cycle continues for 4 hours.
真空、コンデンサおよびヒーターをオフにし、サンプル
を取除く。各回分からのウェハースをトレイ中のウェル
から取除く゛。該ウェハースは白色で各々150mgの
重量であり、その約80m9がアセトアミノフェンであ
る。各回分から得たウェハースを舌に置くと、極く僅か
な苦さのあと味とともにチェジー/クリームフレーバー
を示す。37℃の水中に置くと、該ウェハースは10秒
以内に崩解する。Turn off vacuum, condenser and heater and remove sample. Remove the wafers from each batch from the wells in the tray. The wafers are white and weigh 150 mg each, of which approximately 80 m9 is acetaminophen. When placed on the tongue, the wafers from each batch exhibit a cheesy/cream flavor with a very slight bitter aftertaste. When placed in water at 37°C, the wafer disintegrates within 10 seconds.
実施例7
本実施例は、実施例2のスプレードライした無味のアセ
トアミノフェンおよび以下の他成分を用いた咀しやく錠
の調製について記載している。Example 7 This example describes the preparation of chewable tablets using the spray-dried unflavored acetaminophen of Example 2 and the following other ingredients.
収−立 皿−ユ
実施例2の粉末 500mgステアリン
酸アルミニウム 2mgソルビトール
700乃まで適量合計
’100mg実施例2の粉末は70重量%或いは350
mgのアセトアミノフェンを含有していた。該成分を適
当なミキサー内で混合し、錠剤に成形した。該錠剤を口
の中で咀しやくすると無味でありかつ食品の口あたりを
有していた。ミントフレーバーのような適当なフレーバ
ーを錠剤に処方することにより味を改良できた。Powder of Example 2 500mg Aluminum stearate 2mg Sorbitol
Appropriate amount total up to 700
'100mg Example 2 powder is 70% by weight or 350%
Contains mg of acetaminophen. The ingredients were mixed in a suitable mixer and formed into tablets. When the tablet was chewed in the mouth, it was tasteless and had the mouthfeel of food. The taste could be improved by formulating the tablets with a suitable flavor, such as mint flavor.
特許出願人 アメリカン・ホーム・プロダクツ・コーポ
レイションPatent Applicant: American Home Products Corporation
Claims (6)
トアミノフェン、約15〜30重量%のエチルセルロー
スおよび約15〜30重量%のコロイド状シリカからな
り、該粉末が、アセトアミノフェンおよびエチルセルロ
ースの低アルカノール溶液中のコロイド状シリカの懸濁
液からスプレードライしてなることを特徴とする治療粉
末形のスプレードライしたアセトアミノフェン。(1) consisting of about 40-70% by weight of acetaminophen, about 15-30% by weight of ethyl cellulose and about 15-30% by weight of colloidal silica, based on the weight of the powder, wherein the powder comprises acetaminophen and Spray-dried acetaminophen in the form of a therapeutic powder characterized in that it is spray-dried from a suspension of colloidal silica in a low alkanol solution of ethylcellulose.
第(1)項の粉末。(2) The powder according to item (1) above, wherein the lower alkanol is ethyl alcohol.
トアミノフェン、約15〜30重量%のエチルセルロー
スおよび約15〜30重量%のコロイド状シリカからな
り、アセトアミノフェンおよびエチルセルロースの低ア
ルカノール溶液中のコロイド状シリカの懸濁液をスプレ
ードライしてなることを特徴とする治療粉末形のスプレ
ードライしたアセトアミノフェンの製造方法。(3) consisting of about 40-70% by weight of acetaminophen, about 15-30% by weight of ethylcellulose and about 15-30% by weight of colloidal silica, based on the weight of the powder, a low alkanol of acetaminophen and ethylcellulose; A method for producing spray-dried acetaminophen in the form of a therapeutic powder, comprising spray-drying a suspension of colloidal silica in solution.
を含有し、10秒以内に水で崩解し得る固体の経口投与
用医薬投与形。(4) A solid pharmaceutical dosage form for oral administration containing the therapeutic powder form of paragraph (1) or paragraph (2) above and capable of disintegrating in water within 10 seconds.
る水溶性或いは水分散性の担体材料のネットワークから
なり、該担体材料が該医薬物質に対して不活性であり、
該ネットワークが、医薬物質および溶媒中の担体材料の
溶液からなる固体状態の組成物から溶媒を昇華すること
により得られ、目的とする固体投与形が10秒以内に水
で崩解でき、該医薬物質が前記第(1)項または第(2
)項の治療粉末形であることを特徴とする経口投与用固
体医薬投与形。(5) consisting of a network of pharmaceutically acceptable water-soluble or water-dispersible carrier materials carrying a unit dose of a medicinal substance, said carrier material being inert to said medicinal substance;
The network is obtained by sublimation of the solvent from a solid state composition consisting of a drug substance and a solution of carrier material in a solvent, the intended solid dosage form is disintegrated in water within 10 seconds, and the drug If the substance is
) A solid pharmaceutical dosage form for oral administration, characterized in that it is a therapeutic powder form.
る咀しゃく錠。(6) A chewable tablet containing the powder of item (1) or item (2) above.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US921558 | 1986-10-21 | ||
US06/921,558 US4771077A (en) | 1986-10-21 | 1986-10-21 | Spray dried acetaminophen |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63112515A true JPS63112515A (en) | 1988-05-17 |
JP2550363B2 JP2550363B2 (en) | 1996-11-06 |
Family
ID=25445622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62266140A Expired - Fee Related JP2550363B2 (en) | 1986-10-21 | 1987-10-20 | Spray dried acetaminophen |
Country Status (14)
Country | Link |
---|---|
US (1) | US4771077A (en) |
EP (1) | EP0265226B1 (en) |
JP (1) | JP2550363B2 (en) |
KR (1) | KR950013752B1 (en) |
AT (1) | ATE75602T1 (en) |
AU (1) | AU590980B2 (en) |
CA (1) | CA1298199C (en) |
DE (1) | DE3778825D1 (en) |
ES (1) | ES2032295T3 (en) |
GR (1) | GR3005045T3 (en) |
IE (1) | IE61950B1 (en) |
NZ (1) | NZ222110A (en) |
PH (1) | PH24376A (en) |
ZA (1) | ZA877542B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006248922A (en) * | 2005-03-08 | 2006-09-21 | Hirofumi Takeuchi | Tablet and its manufacturing method |
JP2008542396A (en) * | 2005-06-03 | 2008-11-27 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate acetaminophen formulation |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946684A (en) * | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
US5198228A (en) * | 1989-09-14 | 1993-03-30 | Hoechst-Roussel Pharmaceuticals Inc. | Direct dry compressible acetaminophen tablet |
US5037658A (en) * | 1989-09-14 | 1991-08-06 | Hoechst-Roussel Pharmaceuticals, Inc. | Direct dry compressible acetaminophen composition |
US5130140A (en) * | 1989-09-14 | 1992-07-14 | Hoeschst-Roussel Pharmaceuticals Inc. | Method of making direct dry compressible acetaminophen composition |
EP0421582A1 (en) * | 1989-10-03 | 1991-04-10 | Warner-Lambert Company | Chewable spray dried spheroidal microcapsules and polymer coated microcapsules and method for preparing same |
DK0522128T3 (en) * | 1991-01-30 | 1996-02-26 | Wellcome Found | Water dispersible tablets containing acyclovir |
US5629016A (en) * | 1991-01-30 | 1997-05-13 | Glaxo Wellcome Inc. | Water-dispersible tablets |
GB9215908D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
WO1994028870A1 (en) * | 1993-06-04 | 1994-12-22 | Warner-Lambert Company | Preparations containing silicon dioxide to improve the taste thereof |
US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
CA2169371A1 (en) * | 1993-08-13 | 1995-02-23 | Thomas A. Alexander | Hydrolyzed gelatin as a flavor enhancer in a chewable tablet |
AUPN940796A0 (en) * | 1996-04-23 | 1996-05-16 | F.H. Faulding & Co. Limited | Taste masked pharmaceutical compositions |
AU751497B2 (en) * | 1996-04-23 | 2002-08-15 | Mayne Pharma International Pty Ltd | Taste masked pharmaceutical compositions |
AUPO637197A0 (en) * | 1997-04-23 | 1997-05-15 | F.H. Faulding & Co. Limited | Taste-masked pharmaceutical compositions |
US20040162273A1 (en) * | 2003-01-23 | 2004-08-19 | The Procter & Gamble Company | Powder pharmaceutical compositions |
GB2443793B (en) * | 2006-04-05 | 2010-12-01 | Reckitt Benckiser Healthcare | Product, method of manufacture and use |
US11931227B2 (en) | 2013-03-15 | 2024-03-19 | Cook Medical Technologies Llc | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding |
US20210106717A1 (en) * | 2019-10-10 | 2021-04-15 | Cook Medical Technologies Llc | Bonded powders for the treatment of bodily lesions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49133513A (en) * | 1973-04-27 | 1974-12-21 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
IE45770B1 (en) * | 1976-10-06 | 1982-11-17 | Wyeth John & Brother Ltd | Pharmaceutical dosage forms |
DE3173600D1 (en) * | 1980-05-20 | 1986-03-13 | Mallinckrodt Inc | Spray dried n-acetyl-p-aminophenol compositions and method for manufacture thereof |
JPS58172311A (en) * | 1982-04-02 | 1983-10-11 | Kodama Kk | Prolonged pharmaceutical preparation and its preparation |
DE3306012A1 (en) * | 1983-02-22 | 1984-08-23 | Hoechst Ag, 6230 Frankfurt | Process for the production of free-flowing paracetamol granules |
US4600579A (en) * | 1983-06-07 | 1986-07-15 | Mallinckrodt, Inc. | N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same |
US4533674A (en) * | 1983-10-24 | 1985-08-06 | Basf Wyandotte Corporation | Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid |
AU3880185A (en) * | 1984-02-08 | 1985-08-27 | R.P. Scherer Corporation | Acetaminophen gelatin capsule |
US4710519A (en) * | 1985-09-30 | 1987-12-01 | Basf Corporation | Process for preparing spray dried acetaminophen powder and the powder prepared thereby |
-
1986
- 1986-10-21 US US06/921,558 patent/US4771077A/en not_active Expired - Lifetime
-
1987
- 1987-10-07 ZA ZA877542A patent/ZA877542B/en unknown
- 1987-10-09 NZ NZ222110A patent/NZ222110A/en unknown
- 1987-10-09 AU AU79510/87A patent/AU590980B2/en not_active Expired
- 1987-10-09 CA CA000548996A patent/CA1298199C/en not_active Expired - Lifetime
- 1987-10-13 IE IE274987A patent/IE61950B1/en not_active IP Right Cessation
- 1987-10-20 JP JP62266140A patent/JP2550363B2/en not_active Expired - Fee Related
- 1987-10-20 ES ES198787309253T patent/ES2032295T3/en not_active Expired - Lifetime
- 1987-10-20 AT AT87309253T patent/ATE75602T1/en not_active IP Right Cessation
- 1987-10-20 KR KR1019870011624A patent/KR950013752B1/en not_active IP Right Cessation
- 1987-10-20 DE DE8787309253T patent/DE3778825D1/en not_active Expired - Lifetime
- 1987-10-20 EP EP87309253A patent/EP0265226B1/en not_active Expired - Lifetime
- 1987-10-21 PH PH35967A patent/PH24376A/en unknown
-
1992
- 1992-06-29 GR GR920401373T patent/GR3005045T3/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49133513A (en) * | 1973-04-27 | 1974-12-21 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006248922A (en) * | 2005-03-08 | 2006-09-21 | Hirofumi Takeuchi | Tablet and its manufacturing method |
JP2008542396A (en) * | 2005-06-03 | 2008-11-27 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate acetaminophen formulation |
Also Published As
Publication number | Publication date |
---|---|
CA1298199C (en) | 1992-03-31 |
ZA877542B (en) | 1989-05-30 |
AU7951087A (en) | 1988-04-28 |
KR950013752B1 (en) | 1995-11-15 |
US4771077A (en) | 1988-09-13 |
IE872749L (en) | 1988-04-21 |
KR880004805A (en) | 1988-06-27 |
JP2550363B2 (en) | 1996-11-06 |
ATE75602T1 (en) | 1992-05-15 |
EP0265226A2 (en) | 1988-04-27 |
IE61950B1 (en) | 1994-11-30 |
GR3005045T3 (en) | 1993-05-24 |
NZ222110A (en) | 1989-07-27 |
PH24376A (en) | 1990-06-13 |
DE3778825D1 (en) | 1992-06-11 |
ES2032295T3 (en) | 1993-02-01 |
EP0265226A3 (en) | 1989-07-19 |
AU590980B2 (en) | 1989-11-23 |
EP0265226B1 (en) | 1992-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2542400B2 (en) | Spray dried acetaminophen | |
JP2550362B2 (en) | Spray dried acetaminophen | |
JP2688614B2 (en) | Spray dried ibuprofen | |
JP2550363B2 (en) | Spray dried acetaminophen | |
US4835187A (en) | Spray dried ibuprofen | |
EP0737065B1 (en) | Process for preparing solid pharmaceutical dosage forms | |
US4835186A (en) | Spray dried ibuprofen | |
EP0268383B1 (en) | Spray dried acetaminophen | |
HU201868B (en) | Process for the production of pharmaceutical products in the form of instant granulates, teblets, foam powder or foam tablets | |
SK74396A3 (en) | Organoleptically acceptable oral pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |